Health Canada has cleared Neurotech NA’s orthopedic and pain management devices for distribution in Canada. Receiving clearance are the Kneehab XP Quadriceps Therapy System, the Neurotech Plus Surface Neurostimulation System, and the Recovery – Back Conductive Garment System.
Neurotech Lands Canadian Distribution Rights
1 min read Premium comments
Secondary
The Kneehab XP, which was introduced in the U.S. in early 2010, is a quadriceps rehabilitation system for use following knee injury or surgery. According to company officials, the Kneehab delivers neuromuscular electrical stimulation that has been shown to provide superior rehabilitation results. Neurotech developed the Recovery – Back to strengthen and rehabilitate muscles in the low back and abdomen and to treat low back pain. Surface neurostimulation to these areas is delivered via two separate garments in conjunction with the Neurotech Plus controller.
Neurotech NA is based in Minneapolis, Minnesota and has signed distribution agreements with Rehab Matrix Canada, Inc., headquartered in Nova Scotia, Innovative Medical Supplies, headquartered in Manitoba and Medlines Inc., headquartered in Alberta.
“We are happy with the distribution partners we have in place, and feel they have the market knowledge and experience to truly represent the spirit of the Neurotech product line, ” said Dominic D’Arpino, director of North American sales for Neurotech. “The physician feedback they’re receiving on the products, particularly from sports medicine professionals, has been extremely positive.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.